Print Page | Close Window


December 26, 2016 - 5:01 p.m.
Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9
Printer Friendly Version 
December 19, 2016 - 12:37 p.m.
Kite Pharma Announces Successful Defense of Roberts Patent and Intent to Appeal U.S. Patent and Trademark Office Decision on a Narrow Patent Focused on Select CD28 CAR-T Products
Printer Friendly Version 
December 19, 2016 - 2:04 a.m.
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Vemlidy® for Patients With Chronic Hepatitis B Virus Infection
Printer Friendly Version 
December 13, 2016 - 12:39 p.m.
Kite Pharma and Vitruvian Networks Enter Strategic Partnership to Develop Best-In-Class Logistics and Data Analytics Software for Engineered T-cell Therapies at Commercial Scale
Printer Friendly Version 
December 12, 2016 - 12:40 p.m.
Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine
Printer Friendly Version 
December 08, 2016 - 8:14 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir
Printer Friendly Version 
December 06, 2016 - 12:42 p.m.
Kite Pharma Presents Results of Multi-Center Pivotal ZUMA-1 Trial of Axicabtagene Ciloleucel (KTE-C19) in Aggressive Non-Hodgkin Lymphoma as Late-Breaking Abstract at Annual Meeting of American Society of Hematology
Printer Friendly Version 
December 04, 2016 - 12:43 p.m.
Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)
Printer Friendly Version 
December 01, 2016 - 2:38 p.m.
Kite Pharma Appoints Jian Irish, PhD as Senior Vice President of Supply Chain
Printer Friendly Version 
November 21, 2016 - 2:49 p.m.
Kite Pharma to Present Interim Results from the ZUMA-1 Pivotal Trial of KTE-C19 in a Late-Breaking Session at the 2016 American Society of Hematology Annual Meeting
Printer Friendly Version 
November 16, 2016 - 5:01 p.m.
Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
Printer Friendly Version 
November 16, 2016 - 4:16 p.m.
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis
Printer Friendly Version 
November 15, 2016 - 5:42 p.m.
Gilead Sciences to Present at the Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
Printer Friendly Version 
November 14, 2016 - 4:32 p.m.
Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016
Printer Friendly Version 
November 11, 2016 - 7:27 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
November 10, 2016 - 1:07 p.m.
U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
November 09, 2016 - 2:50 p.m.
Kite Pharma Reports Third Quarter 2016 Financial Results
Printer Friendly Version 
November 03, 2016 - 2:52 p.m.
Kite Pharma to Present KTE-C19 Data from Interim Analysis of the ZUMA-1 Pivotal Trial in Patients with Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL) at the 2016 American Society Hematology Annual Meeting
Printer Friendly Version 
November 02, 2016 - 2:56 p.m.
Kite Pharma to Report Third Quarter 2016 Financial Results on November 9, 2016
Printer Friendly Version 
November 01, 2016 - 4:04 p.m.
Gilead Sciences Announces Fourth Quarter 2016 Dividend
Printer Friendly Version 
November 01, 2016 - 4:02 p.m.
Gilead Sciences Announces Third Quarter 2016 Financial Results
Printer Friendly Version 
October 28, 2016 - 2:57 p.m.
Kite Pharma to Present at November 2016 Investor Conferences
Printer Friendly Version 
October 25, 2016 - 5:02 p.m.
Gilead Sciences to Release Third Quarter 2016 Financial Results on Tuesday, November 1, 2016
Printer Friendly Version 
October 24, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7
Printer Friendly Version 
October 24, 2016 - 6:25 a.m.
Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens
Printer Friendly Version 
October 20, 2016 - 10:08 a.m.
Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients
Printer Friendly Version 
October 20, 2016 - 10:06 a.m.
Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)
Printer Friendly Version 
October 19, 2016 - 9:59 a.m.
Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day
Printer Friendly Version 
October 13, 2016 - 10:04 a.m.
Kite Pharma Appoints Chris Nowers as Head of Europe to Lead Commercial Operations and Advance the Company's CAR/TCR Therapy Portfolio in the Region
Printer Friendly Version 
October 11, 2016 - 10:11 a.m.
Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry-Leading CAR/TCR Pipeline, Next Generation Research and Development, and KTE-C19 Launch Readiness
Printer Friendly Version 
October 07, 2016 - 10:13 a.m.
Kite Pharma Presents 12-Month Follow-Up Data from ZUMA-1 Phase 1 at the European Society for Medical Oncology (ESMO) Annual Congress
Printer Friendly Version 
October 06, 2016 - 10:15 a.m.
Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Printer Friendly Version 
September 29, 2016 - 10:18 a.m.
Kite Pharma Names Christine Cassiano as Senior Vice President of Corporate Communications and Investor Relations
Printer Friendly Version 
September 27, 2016 - 4:06 p.m.
Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
Printer Friendly Version 
September 26, 2016 - 10:22 a.m.
Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL)
Printer Friendly Version 
September 21, 2016 - 5:01 p.m.
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Printer Friendly Version 
September 20, 2016 - 10:40 a.m.
Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS
Printer Friendly Version 
September 15, 2016 - 10:02 p.m.
Gilead Prices $5 Billion of Senior Unsecured Notes
Printer Friendly Version 
September 06, 2016 - 1:02 p.m.
Gilead Sciences to Present at Three Upcoming Investor Conferences in September
Printer Friendly Version 
August 31, 2016 - 10:44 a.m.
Kite Pharma to Participate in September 2016 Investor Conferences
Printer Friendly Version 
August 23, 2016 - 8:57 a.m.
Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
Printer Friendly Version 
August 22, 2016 - 11:50 a.m.
European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1
Printer Friendly Version 
August 19, 2016 - 10:46 a.m.
Kite Pharma Advisors and Scientific Pioneers in Cancer Immunotherapy Receive Prestigious Cellular Immune Therapy Award
Printer Friendly Version 
August 08, 2016 - 10:47 a.m.
Kite Pharma Reports Second Quarter 2016 Financial Results
Printer Friendly Version 
August 03, 2016 - 10:59 a.m.
Kite Pharma to Present at the Canaccord Genuity 36th Annual Growth Conference
Printer Friendly Version 
August 01, 2016 - 11:01 a.m.
Kite Pharma to Report Second Quarter 2016 Financial Results on August 8, 2016
Printer Friendly Version 
July 27, 2016 - 11:03 a.m.
Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
Printer Friendly Version 
July 25, 2016 - 4:11 p.m.
Gilead Sciences Announces Third Quarter 2016 Dividend
Printer Friendly Version 
July 25, 2016 - 4:09 p.m.
Gilead Sciences Announces Second Quarter 2016 Financial Results
Printer Friendly Version 
July 25, 2016 - 11:04 a.m.
Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies
Printer Friendly Version 
July 22, 2016 - 7:19 a.m.
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Printer Friendly Version 
July 21, 2016 - 4:32 p.m.
Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Printer Friendly Version 
July 18, 2016 - 5:02 p.m.
Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
Printer Friendly Version 
July 08, 2016 - 6:52 a.m.
European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
July 07, 2016 - 11:12 a.m.
Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Pivotal Multi-Center Phase 2 Study of KTE-C19 (ZUMA-1)
Printer Friendly Version 
June 28, 2016 - 10:26 a.m.
U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
June 23, 2016 - 7:54 a.m.
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
Printer Friendly Version 
June 20, 2016 - 4:16 p.m.
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
Printer Friendly Version 
June 20, 2016 - 11:39 a.m.
Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)
Printer Friendly Version 
June 20, 2016 - 11:28 a.m.
Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility
Printer Friendly Version 
June 20, 2016 - 8:31 a.m.
Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Printer Friendly Version 
June 13, 2016 - 5:01 p.m.
Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
Printer Friendly Version 
June 09, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
Printer Friendly Version 
June 08, 2016 - 4:19 p.m.
Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress
Printer Friendly Version 
June 07, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
Printer Friendly Version 
June 06, 2016 - 4:38 p.m.
Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma
Printer Friendly Version 
June 06, 2016 - 4:22 p.m.
Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)
Printer Friendly Version 
June 06, 2016 - 4:21 p.m.
Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma
Printer Friendly Version 
June 02, 2016 - 4:41 p.m.
Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches' for CAR T-Cell Immunotherapies
Printer Friendly Version 
June 01, 2016 - 4:46 p.m.
Kite Pharma Granted Access to Priority Medicines (PRIME) Regulatory Support for KTE-C19 in the Treatment of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)
Printer Friendly Version 
May 31, 2016 - 4:47 p.m.
Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
Printer Friendly Version 
May 27, 2016 - 4:48 p.m.
Kite Pharma to Present at June 2016 Investor Conferences
Printer Friendly Version 
May 27, 2016 - 7:27 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Printer Friendly Version 
May 24, 2016 - 4:30 p.m.
Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy
Printer Friendly Version 
May 20, 2016 - 5:01 p.m.
Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23
Printer Friendly Version 
May 16, 2016 - 4:49 p.m.
Kite Pharma Expands Leadership Team, Appoints Paul L. Jenkinson as Chief Financial Officer
Printer Friendly Version 
May 09, 2016 - 5:02 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10
Printer Friendly Version 
May 09, 2016 - 4:55 p.m.
Kite Pharma Reports First Quarter 2016 Financial Results
Printer Friendly Version 
May 03, 2016 - 4:56 p.m.
Kite Pharma to Report First Quarter 2016 Financial Results on May 9, 2016
Printer Friendly Version 
May 02, 2016 - 5:02 p.m.
Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications
Printer Friendly Version 
April 29, 2016 - 8:22 a.m.
European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV
Printer Friendly Version 
April 28, 2016 - 5:06 p.m.
Kite Pharma Announces Presentations at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Printer Friendly Version 
April 28, 2016 - 4:04 p.m.
Gilead Sciences Announces Second Quarter 2016 Dividend
Printer Friendly Version 
April 28, 2016 - 4:04 p.m.
Gilead Sciences Announces First Quarter 2016 Financial Results
Printer Friendly Version 
April 25, 2016 - 7:11 a.m.
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV
Printer Friendly Version 
April 21, 2016 - 5:01 p.m.
Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
Printer Friendly Version 
April 19, 2016 - 5:09 p.m.
Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting
Printer Friendly Version 
April 18, 2016 - 5:10 p.m.
Kite Pharma Commends Scientific Advisory Board Members on Awards Received from the American Association of Cancer Research (AACR)
Printer Friendly Version 
April 16, 2016 - 5:14 p.m.
Kite Pharma Announces Review of National Cancer Institute's Manufacturing Facilities
Printer Friendly Version 
April 16, 2016 - 7:30 a.m.
Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
Printer Friendly Version 
April 16, 2016 - 6:30 a.m.
Gilead Presents New Data Highlighting Progress in Liver Fibrosis
Printer Friendly Version 
April 15, 2016 - 5:16 p.m.
Kite Pharma Announces Key Presentations on KTE-C19 and Engineered Cell Therapy Pipeline Programs at the Annual Meeting of the American Association for Cancer Research (AACR)
Printer Friendly Version 
April 15, 2016 - 4:31 a.m.
Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Printer Friendly Version 
April 04, 2016 - 2:58 p.m.
U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
Printer Friendly Version 
April 04, 2016 - 8:31 a.m.
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases
Printer Friendly Version 
March 31, 2016 - 2:04 a.m.
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
Printer Friendly Version 
March 17, 2016 - 5:30 p.m.
Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma
Printer Friendly Version 
March 16, 2016 - 5:33 p.m.
Kite Pharma Deepens Cell Manufacturing and Operations Expertise with Appointment of Tim Moore
Printer Friendly Version 
March 16, 2016 - 5:32 p.m.
Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)
Printer Friendly Version 
March 10, 2016 - 5:01 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15
Printer Friendly Version 
March 04, 2016 - 6:00 p.m.
Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
Printer Friendly Version 
March 04, 2016 - 4:02 p.m.
Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
Printer Friendly Version 
March 03, 2016 - 5:35 p.m.
Kite Pharma to Present at March 2016 Investor Conferences
Printer Friendly Version 
March 01, 2016 - 2:07 p.m.
U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Printer Friendly Version 
February 29, 2016 - 5:37 p.m.
Kite Pharma Reports Fourth Quarter and Full-Year 2015 Financial Results
Printer Friendly Version 
February 26, 2016 - 7:53 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV
Printer Friendly Version 
February 25, 2016 - 10:38 a.m.
European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
February 24, 2016 - 5:41 p.m.
Kite Pharma to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
Printer Friendly Version 
February 24, 2016 - 5:38 p.m.
Kite Pharma Augments Commercial Leadership Team
Printer Friendly Version 
February 24, 2016 - 12:10 p.m.
Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
Printer Friendly Version 
February 23, 2016 - 5:02 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24
Printer Friendly Version 
February 23, 2016 - 12:12 p.m.
Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens
Printer Friendly Version 
February 22, 2016 - 8:32 a.m.
Gilead Launches New Grants Program to Support HIV Cure
Printer Friendly Version 
February 16, 2016 - 5:42 p.m.
Kite Pharma to Participate in the 2016 RBC Capital Markets Global Healthcare Conference
Printer Friendly Version 
February 16, 2016 - 8:32 a.m.
U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
Printer Friendly Version 
February 08, 2016 - 5:02 p.m.
Gilead Sciences to Participate in Two Upcoming Investor Conferences
Printer Friendly Version 
February 02, 2016 - 4:02 p.m.
Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
Printer Friendly Version 
February 02, 2016 - 4:01 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results
Printer Friendly Version 
February 01, 2016 - 5:00 p.m.
Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources
Printer Friendly Version 
February 01, 2016 - 9:04 a.m.
European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Printer Friendly Version 
January 29, 2016 - 8:00 a.m.
Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director
Printer Friendly Version 
January 26, 2016 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016
Printer Friendly Version 
January 19, 2016 - 4:31 p.m.
Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib
Printer Friendly Version 
January 13, 2016 - 5:44 p.m.
SANTA MONICA, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection. Under the terms of the agreement, Kite Pharma EU will partner with the LUMC Department of Clinical Oncology
Printer Friendly Version 
January 13, 2016 - 1:31 a.m.
Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib
Printer Friendly Version 
January 12, 2016 - 8:31 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Printer Friendly Version 
January 08, 2016 - 4:01 p.m.
Gilead Sciences to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11
Printer Friendly Version 
January 07, 2016 - 5:45 p.m.
Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies
Printer Friendly Version 
January 06, 2016 - 5:47 p.m.
Kite Pharma to Present at the 34th Annual J.P. Morgan Healthcare Conference
Printer Friendly Version 
January 05, 2016 - 6:01 p.m.
Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis
Printer Friendly Version 
January 05, 2016 - 8:31 a.m.
Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Printer Friendly Version 
January 04, 2016 - 4:31 p.m.
Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection
Printer Friendly Version